 GERMANTOWN, Md. , Dec. 19, 2022 PRNewswire -- Precigen, Inc. Nasdaq: PGEN, a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced Helen Sabzevari, PhD, President and CEO of Precigen, will present a corporate and clinical overview at the 41st Annual J.P. 